His main research concerns Heart failure, Internal medicine, Cardiology, Ejection fraction and Intensive care medicine. His research integrates issues of Serelaxin, Placebo, Heart disease and Blood pressure in his study of Heart failure. The Internal medicine study which covers Endocrinology that intersects with Receptor.
The study incorporates disciplines such as Rolofylline, Systole and Renal function in addition to Cardiology. His Ejection fraction research integrates issues from Anesthesia, Cohort and Confidence interval. The concepts of his Intensive care medicine study are interwoven with issues in Clinical trial and Nesiritide.
Heart failure, Internal medicine, Cardiology, Intensive care medicine and Ejection fraction are his primary areas of study. His studies in Heart failure integrate themes in fields like Serelaxin, Placebo, Clinical trial and Blood pressure. His Hazard ratio, Renal function, Confidence interval, Rolofylline and Omecamtiv mecarbil investigations are all subjects of Internal medicine research.
In his study, Activator is inextricably linked to Cardiac myosin, which falls within the broad field of Cardiology. His Intensive care medicine study combines topics from a wide range of disciplines, such as Levosimendan, Randomized controlled trial, Nesiritide and Acute decompensated heart failure. His work deals with themes such as Stroke, Anesthesia and Warfarin, which intersect with Ejection fraction.
His primary areas of investigation include Heart failure, Internal medicine, Cardiology, Ejection fraction and Clinical trial. His study in Heart failure is interdisciplinary in nature, drawing from both Inotrope, Placebo, Clinical endpoint and Intensive care medicine. His work on Expert consensus as part of general Intensive care medicine research is frequently linked to Quality of life, thereby connecting diverse disciplines of science.
In general Internal medicine, his work in Kansas City Cardiomyopathy Questionnaire, Brain natriuretic peptide, Systole and Troponin is often linked to In patient linking many areas of study. His work carried out in the field of Cardiology brings together such families of science as Serelaxin, Omecamtiv mecarbil, Randomized controlled trial and Hazard ratio. His Ejection fraction research is multidisciplinary, incorporating elements of Cardiac function curve, Quality of life, Contractility and Isovolumic relaxation time.
John R. Teerlink spends much of his time researching Heart failure, Internal medicine, Cardiology, Ejection fraction and Clinical trial. His Heart failure research includes themes of Inotrope, Placebo, Omecamtiv mecarbil and Randomized controlled trial. His work in the fields of Internal medicine, such as Troponin, Hazard ratio and Confidence interval, overlaps with other areas such as Pandemic and Risk of infection.
His Cardiomyopathy and Heart malformation study in the realm of Cardiology connects with subjects such as Severe acute respiratory syndrome coronavirus 2 and Patient safety. His Mildly reduced ejection fraction study in the realm of Ejection fraction interacts with subjects such as In patient. His biological study spans a wide range of topics, including Drug development, Drug approval, Physical function and Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effect of nesiritide in patients with acute decompensated heart failure.
C. M. O'Connor;R. C. Starling;A. F. Hernandez;P. W. Armstrong.
The New England Journal of Medicine (2011)
Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.
Maria Rosa Costanzo;Maya E. Guglin;Mitchell T. Saltzberg;Mariell L. Jessup.
Journal of the American College of Cardiology (2007)
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
John R Teerlink;Gad Cotter;Beth A Davison;G Michael Felker.
The Lancet (2013)
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Milton Packer;John J. V. McMurray;Akshay S. Desai;Jianjian Gong.
Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm
Shunichi Homma;John L.P. Thompson;Patrick M. Pullicino;Bruce Levin.
The New England Journal of Medicine (2012)
Rolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart Failure
Barry M. Massie;Christopher M. O'Connor;Marco Metra;Piotr Ponikowski.
The New England Journal of Medicine (2010)
Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study
John R Teerlink;Marco Metra;G Michael Felker;Piotr Ponikowski.
The Lancet (2009)
Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program: Correlation With Outcomes
Marco Metra;Gad Cotter;Beth A. Davison;G. Michael Felker.
Journal of the American College of Cardiology (2013)
Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure
Milton Packer;Wilson Colucci;Lloyd Fisher;Barry M. Massie.
Jacc-Heart Failure (2013)
Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) Trial
Michael R. Zile;William H. Gaasch;Inder S. Anand;Markus Haass.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: